eMedicine Specialties > Endocrinology > Parathyroid Gland

Pseudohypoparathyroidism: Follow-up

Author: Mini R Abraham, MD, Consulting Staff, Saint Luke's Medical Group
Coauthor(s): Romesh Khardori, MD, Chief, Division of Endocrinology, Metabolism and Molecular Medicine, Professor, Department of Internal Medicine, Southern Illinois University School of Medicine
Contributor Information and Disclosures

Updated: Aug 5, 2009

Follow-up

Further Outpatient Care

  • Monitor therapy through regular serum and urine calcium measurements. Exercise caution to avoid renal or hypercalcemic complications.
  • Monitor serum PTH levels with a goal of maintaining serum PTH levels within the reference range.

Patient Education

For excellent patient education resources, see eMedicine's Osteoporosis and Bone Health Center.

Miscellaneous

Medicolegal Pitfalls

  • Failure to initially treat all patients with severe symptomatic hypocalcemia with intravenous calcium
  • Failure to maintain serum total and ionized calcium levels within the reference range to avoid hypercalciuria and to suppress PTH levels to normal
  • Failure to slowly infuse calcium (because of the possible adverse effects of cardiac conduction defects)
 


More on Pseudohypoparathyroidism

Overview: Pseudohypoparathyroidism
Differential Diagnoses & Workup: Pseudohypoparathyroidism
Treatment & Medication: Pseudohypoparathyroidism
Follow-up: Pseudohypoparathyroidism
Multimedia: Pseudohypoparathyroidism
References
Further Reading
[ CLOSE WINDOW ]

References

  1. Bastepe M. The GNAS locus and pseudohypoparathyroidism. Adv Exp Med Biol. 2008;626:27-40. [Medline].

  2. Davies SJ, Hughes HE. Imprinting in Albright's hereditary osteodystrophy. J Med Genet. Feb 1993;30(2):101-3. [Medline].

  3. Juppner H, Schipani E, Bastepe M, et al. The gene responsible for pseudohypoparathyroidism type Ib is paternally imprinted and maps in four unrelated kindreds to chromosome 20q13.3. Proc Natl Acad Sci U S A. Sep 29 1998;95(20):11798-803. [Medline].

  4. Wu WI, Schwindinger WF, Aparicio LF, Levine MA. Selective resistance to parathyroid hormone caused by a novel uncoupling mutation in the carboxyl terminus of G alpha(s). A cause of pseudohypoparathyroidism type Ib. J Biol Chem. Jan 5 2001;276(1):165-71. [Medline].

  5. Bliek J, Verde G, Callaway J, et al. Hypomethylation at multiple maternally methylated imprinted regions including PLAGL1 and GNAS loci in Beckwith-Wiedemann syndrome. Eur J Hum Genet. May 2009;17(5):611-9. [Medline].

  6. Mahmud FH, Linglart A, Bastepe M, et al. Molecular diagnosis of pseudohypoparathyroidism type Ib in a family with presumed paroxysmal dyskinesia. Pediatrics. Feb 2005;115(2):e242-4. [Medline].

  7. Shalitin S, Davidovits M, Lazar L, et al. Clinical heterogeneity of pseudohypoparathyroidism: from hyper- to hypocalcemia. Horm Res. 2008;70(3):137-44. [Medline].

  8. Balavoine AS, Ladsous M, Velayoudom FL, et al. Hypothyroidism in patients with pseudohypoparathyroidism type Ia: clinical evidence of resistance to TSH and TRH. Eur J Endocrinol. Oct 2008;159(4):431-7. [Medline].

  9. Freson K, Izzi B, Labarque V, et al. GNAS defects identified by stimulatory G protein alpha-subunit signalling studies in platelets. J Clin Endocrinol Metab. Dec 2008;93(12):4851-9. [Medline].

  10. Weinhaeusel A, Thiele S, Hofner M, et al. PCR-based analysis of differentially methylated regions of GNAS enables convenient diagnostic testing of pseudohypoparathyroidism type Ib. Clin Chem. Sep 2008;54(9):1537-45. [Medline].

  11. Bastepe M, Juppner H. Pseudohypoparathyroidism. New insights into an old disease. Endocrinol Metab Clin North Am. Sep 2000;29(3):569-89. [Medline].

  12. Bringhurst FR, Demay MB, Kronenberg HM. Hormones and disorders of mineral metabolism. In: Williams Textbook of Endocrinology. 9th ed. Philadelphia, Pa: WB Saunders Company; 1998:1155-1209.

  13. Farfel Z, Bourne HR, Iiri T. The expanding spectrum of G protein diseases. N Engl J Med. Apr 1 1999;340(13):1012-20. [Medline].

  14. Germain-Lee EL, Groman J, Crane JL, et al. Growth hormone deficiency in pseudohypoparathyroidism type 1a: another manifestation of multihormone resistance. J Clin Endocrinol Metab. Sep 2003;88(9):4059-69. [Medline].

  15. Iiri T, Herzmark P, Nakamoto JM, et al. Rapid GDP release from Gs alpha in patients with gain and loss of endocrine function. Nature. Sep 8 1994;371(6493):164-8. [Medline].

  16. Jan de Beur SM, Ding CL, LaBuda MC, et al. Pseudohypoparathyroidism 1b: exclusion of parathyroid hormone and its receptors as candidate disease genes. J Clin Endocrinol Metab. Jun 2000;85(6):2239-46. [Medline].

  17. Levine MA. Hypoparathyroidism and pseudohypoparathyroidism. In: DeGroot, Jameson, et al, eds. Endocrinology. 4th ed. Philadelphia, Pa: WB Saunders Company; 2001:1133-1153.

  18. Levine MA, Jap TS, Hung W. Infantile hypothyroidism in two sibs: an unusual presentation of pseudohypoparathyroidism type Ia. J Pediatr. Dec 1985;107(6):919-22. [Medline].

  19. Long DN, McGuire S, Levine MA, et al. Body mass index differences in pseudohypoparathyroidism type 1a versus pseudopseudohypoparathyroidism may implicate paternal imprinting of Galpha(s) in the development of human obesity. J Clin Endocrinol Metab. Mar 2007;92(3):1073-9. [Medline]. [Full Text].

  20. Mantovani G, Bondioni S, Linglart A, Maghnie M, Cisternino M, Corbetta S. Genetic analysis and evaluation of resistance to thyrotropin and growth hormone-releasing hormone in pseudohypoparathyroidism type ib. J Clin Endocrinol Metab. Sep 2007;92(9):3738-42. [Medline].

  21. Mantovani G, Maghnie M, Weber G, et al. Growth hormone-releasing hormone resistance in pseudohypoparathyroidism type ia: new evidence for imprinting of the Gs alpha gene. J Clin Endocrinol Metab. Sep 2003;88(9):4070-4. [Medline].

  22. Murray TM, Rao LG, Wong MM, et al. Pseudohypoparathyroidism with osteitis fibrosa cystica: direct demonstration of skeletal responsiveness to parathyroid hormone in cells cultured from bone. J Bone Miner Res. Jan 1993;8(1):83-91. [Medline].

  23. Nakamoto JM, Zimmerman D, Jones EA, et al. Concurrent hormone resistance (pseudohypoparathyroidism type Ia) and hormone independence (testotoxicosis) caused by a unique mutation in the G alpha s gene. Biochem Mol Med. Jun 1996;58(1):18-24. [Medline].

  24. Nakamura Y, Matsumoto T, Tamakoshi A, et al. Prevalence of idiopathic hypoparathyroidism and pseudohypoparathyroidism in Japan. J Epidemiol. Jan 2000;10(1):29-33. [Medline].

  25. Pearson DW, Durward WF, Fogelman I, et al. Pseudohypoparathyroidism presenting as severe Parkinsonism. Postgrad Med J. Jul 1981;57(669):445-7. [Medline].

  26. Root AW, Diamond FB Jr, Mimouni FB. Parathyroid and vitamin D-related disorders in children and adolescents. In: Pediatric Endocrinology. ed. Philadelphia, Pa: WB Saunders Company; 1996:477-507.

  27. Shriraam M, Bhansali A, Velayutham P. Vitamin D deficiency masquerading as pseudohypoparathyroidism type 2. J Assoc Physicians India. Jun 2003;51:619-20. [Medline].

  28. Srivastava T, Alon US. Stage I vitamin D-deficiency rickets mimicking pseudohypoparathyroidism type II. Clin Pediatr (Phila). May 2002;41(4):263-8. [Medline].

  29. Vlaeminck-Guillem V, D'herbomez M, Pigny P, et al. Pseudohypoparathyroidism Ia and hypercalcitoninemia. J Clin Endocrinol Metab. Jul 2001;86(7):3091-6. [Medline].

  30. Wagar G, Lehtivuori J, Salven I, et al. Pseudohypoparathyroidism associated with hypercalcitoninaemia. Acta Endocrinol (Copenh). Jan 1980;93(1):43-8. [Medline].

  31. Yamamoto Y, Noto Y, Saito M, et al. Spinal cord compression by heterotopic ossification associated with pseudohypoparathyroidism. J Int Med Res. Nov-Dec 1997;25(6):364-8. [Medline].

[ CLOSE WINDOW ]

Keywords

pseudohypoparathyroidism, parathyroid, parathyroid hormone, hypocalcemia, parathyroid gland, parathyroid glands, PTH, pseudopseudohypoparathyroidism, hyperphosphatemia, Albright hereditary osteodystrophy, Albright's hereditary osteodystrophy, pseudo-PHP, stimulatory G protein, Gsa, GNAS1, testotoxicosis, dental hypoplasia, brachymetacarpals, brachymetatarsals, brachydactyly

[ CLOSE WINDOW ]

Contributor Information and Disclosures

Author

Mini R Abraham, MD, Consulting Staff, Saint Luke's Medical Group
Mini R Abraham, MD is a member of the following medical societies: American Association of Clinical Endocrinologists and Endocrine Society
Disclosure: Glaxo Smith Kline Honoraria Speaking and teaching; Novo Nordisk Honoraria Speaking and teaching

Coauthor(s)

Romesh Khardori, MD, Chief, Division of Endocrinology, Metabolism and Molecular Medicine, Professor, Department of Internal Medicine, Southern Illinois University School of Medicine
Romesh Khardori, MD is a member of the following medical societies: American Association of Clinical Endocrinologists, American College of Physicians, American Diabetes Association, American Federation for Medical Research, American Medical Association, American Society of Andrology, Endocrine Society, and Illinois State Medical Society
Disclosure: Nothing to disclose.

Medical Editor

Stanley Wallach, MD, Executive Director, American College of Nutrition; Clinical Professor, Department of Medicine, New York University School of Medicine
Stanley Wallach, MD is a member of the following medical societies: American Society for Bone and Mineral Research, American Society for Clinical Investigation, American Society for Clinical Nutrition, American Society for Nutritional Sciences, Association of American Physicians, and Endocrine Society
Disclosure: Nothing to disclose.

Pharmacy Editor

Francisco Talavera, PharmD, PhD, Senior Pharmacy Editor, eMedicine
Disclosure: eMedicine Salary Employment

Managing Editor

Kent Wehmeier, MD, Professor, Department of Internal Medicine, Division of Endocrinology, Diabetes, and Metabolism, St Louis University School of Medicine
Kent Wehmeier, MD is a member of the following medical societies: American Society of Hypertension, Endocrine Society, and International Society for Clinical Densitometry
Disclosure: Nothing to disclose.

CME Editor

Mark Cooper, MBBS, PhD, FRACP, Head, Diabetes & Metabolism Division, Baker Heart Research Institute, Professor of Medicine, Monash University
Disclosure: Nothing to disclose.

Chief Editor

George T Griffing, MD, Professor of Medicine, St Louis University School of Medicine
George T Griffing, MD is a member of the following medical societies: American Association for the Advancement of Science, American College of Medical Practice Executives, American College of Physician Executives, American College of Physicians, American Diabetes Association, American Federation for Medical Research, American Heart Association, Central Society for Clinical Research, Endocrine Society, International Society for Clinical Densitometry, and Southern Society for Clinical Investigation
Disclosure: Nothing to disclose.

 
 
HONcode

We subscribe to the
HONcode principles of the
Health On the Net Foundation

All material on this website is protected by copyright, Copyright© 1994- by Medscape.
This website also contains material copyrighted by 3rd parties.

DISCLAIMER: The content of this Website is not influenced by sponsors. The site is designed primarily for use by qualified physicians and other medical professionals. The information contained herein should NOT be used as a substitute for the advice of an appropriately qualified and licensed physician or other health care provider. The information provided here is for educational and informational purposes only. In no way should it be considered as offering medical advice. Please check with a physician if you suspect you are ill.